The Japanese Journal of Nephrology and Pharmacotherapy (JJNP): Guidelines for Authors
1. Submission requirements
The corresponding author must be a member of the Japanese Society of Nephrology andPharmacotherapy (JSNP). However, this membership requirement is waived for submissions
solicited by the JSNP.
2. Manuscript contentI.

The article must pertain to nephrology and pharmacotherapy, must contain legitimate andscientific research, and must not have been presented elsewhere or be scheduled for
publication in another journal.

II.

Authors may submit a review article, original article, brief report, or case report. A
definition of each article type is provided below.
a) Review articles: Summarize and analyze previous articles on single or multiple topics.
b) Original articles: Report new findings based on original research.
c) Brief reports:

Describe new findings and warrant expedited reporting due to theirpotential social implications, despite often being based on fragmented research.
d) Case reports: Describe the authors’ own experiences and can make a significant
contribution to clinical research in nephrology and pharmacotherapy.
3. Ethics
I.

Human research shall be conducted according to the principles of the Helsinki
Declaration 1) and shall adhere to the “Ethical Guidelines for Medical and Health Research
Involving Human Subjects”2) issued by the Ministry of Health, Labour and Welfare(MHLW) of Japan.

II.

Research relating to genetic diseases and human genome/gene analysis shall adhere to the“Ethical Guidelines for Human Genome/Gene Analysis Research” 2) issued by the MHLW.

III.

Animal research shall adhere to the “Fundamental Guidelines for Proper Conduct ofAnimal Experiments and Related Activities in Academic Research Institutions” 3) issued
by the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan.

IV.

All research should be based on the latest version of each guideline, and the article should
clearly state the ethics guidelines followed.

V.

Where approval has been granted by an ethics review board, provide the approval number.
1

Helsinki Declaration (Japanese translation of the World Medical Association document prepared by the Japan MedicalAssociation)
http://www.med.or.jp/wma/helsinki.html
2

MHLW web page on research guidelines:
http://www.mhlw.go.jp/stf/seisakunitsuite/bunya/hokabunya/kenkyujigyou/i-kenkyu/3

MEXT web page on animal & other research guidelines:
http://www.lifescience.mext.go.jp/policies/dobutsu.html

5

4. Manuscript format
I.

The manuscript must be written in either Japanese or English.

II.

The manuscript must adhere to the attached “JJNP Style Guide”.

III.

The manuscript must contain a title, the name(s) and affiliation(s) of the author(s), abstract,keywords, and body.

IV.

Manuscripts submitted in Japanese must be accompanied by an English translation of thetitle, author name(s) and affiliation(s), keywords, and abstract. Manuscripts submitted inEnglish must be accompanied by a Japanese translation of the abstract and key words.

V.

Manuscripts submitted in English must have been proofread by a native English speaker,
and the name and affiliation of the proofreader must be provided. A certificate issued by
the proofreading organization/company must also be provided. Any revisions to theEnglish manuscript must undergo further proofreading, and the signature or certificate of
the proofreader must be submitted in PDF format via post to the JSNP AdministrativeOffice. Authors may be charged for the cost of any corrections to the English manuscript,
and English abstract in Japanese manuscript deemed necessary by the Editorial Board.

VI.

Authors must include a conflict of interest (COI) statement at the end of the manuscript.

VII.

Submit the manuscript together with the submission application (provided on the JSNP
website) after filling out all required information and after going through the provided
Guidelines for Authors checklist.

5. Publication charges, manuscript fees, and offprint charges
I.

Authors will not be charged for publication.

II.

Manuscript fees (approximately 5,000 yen per one printed page) will be paid for author inaccordance with the editorial board rules when JSNP requested for a contribution to JJNP.

III.

The electronic reprint of the published article will be provided free of charge. Hard-copy
reprints can be ordered in packs of 10 by sending a reprint order form with galley proofs.
Authors will be charged 3,000 yen for up to 50 reprints, and 2,000 yen for each additional
50 reprints (prices do not include consumption tax).

6. Acceptance and proofreading
I.

Manuscripts are generally reviewed by two or more peer reviewers under a “multiple peer
review system.” The Editorial Board makes the final decision on publication based on theReviewers’ opinions.

II.

When revisions are requested, revised manuscripts should be submitted within 60 days
unless otherwise specified, otherwise they will be treated as new submissions.

III.

Authors are responsible for the first proofreading of the approved manuscript, and the
Editorial Board will proofread subsequent drafts. Only typographical errors should becorrected in the galley proofs.
57. Copyright and responsibility of authors
I.

Authors are responsible for the content of their manuscripts.

II.

For collaborative studies, co-authors should appoint one author (denoted with a superscript
asterisk: *) to represent their moral rights in accordance with Article 64-3 of Japan’s
Copyright Act. The Editorial Board will regard this author as the person responsible forthe content of the manuscript, and for other substantive responsibilities related topublication.

III.

Copyright will be transferred to JSNP if the manuscript is accepted.

8. Conflict of interest
I.

Authors must disclose any relationships (financial or otherwise) with corporate orcommercial entities that pose a conflict of interest (COI) in terms of the content of themanuscript.

II.

Refer to the attached “JSNP Guidelines for Conflict of Interest” for specific details on thetypes of COI that must be disclosed in the manuscript. If authors have no conflict of interest
to declare, the statement “Conflict of interest declaration: None.” must be included.

9. Penalties for duplicate submission, plagiarism, falsification, and fabrication
I.

Manuscripts may be refused or withdrawn from publication in the event of duplicate
submission, plagiarism, falsification, or fabrication.

II.

Authors (including co-authors) who submit a manuscript that falls under the provisions ofthe previous item will be prohibited from submitting a new manuscript to JJNP for a periodof five years.

III.

JSNP reserves the right to provide details of the above-mentioned transgressions to theauthors’ employers and/or affiliated organizations, and to request an investigation.

10. Print submissions
Manuscripts should be sent to the following address as an email attachment together with thechecklist and other required forms.
Administrative Office, Japanese Society of Nephrology and Pharmacotherapy
Email: maf-jsnp@mynavi.jp
Mainichi Academic Forum, 9F Palaceside Bldg.,
1-1-1, Hitotsubashi, Chiyoda-ku, Tokyo 100-0003
Tel: 03-6267-4550: Fax: 03-6267-4555.
11. Revisions to the Guidelines for Authors

5Any revisions to the Guidelines for Authors must first be discussed by the JSNP Board ofDirectors.
Additional Regulations
1. The Guidelines for Authors came into effect on December 1, 2011.
2. Revised: February 1, 2012
3. Revised: March 23, 2012
4. Revised: April 4, 2012
5. Revised: May 11, 2012
6. Revised: May 15, 2012
7. Revised: June 5, 2012
8. Revised: October 12, 2013
9. Revised: October 25, 2013
10. Revised: June 13, 2014
11. Revised: May 1, 2016
12. Revised: July 1, 2016
13. Revised: July 1, 2017
14. Revised: June 1, 201815. Revised: February 28, 2020
16. Revised: May 1, 2020
17. Revised: September 15, 20205

Attachments
JJNP Guidelines for Conflict of Interest
JJNP requires all authors to disclose all relevant conflicts of interest (see below) forthe past one year from the first submission date. COIs should be stated at the end ofthe main text.

Conflicts of interest to be declareda. Payment for lectures: Total annual payment of 500,000 yen or more received froma single company or organization
b. Payment for articles: Total annual payment of 500,000 yen or more received froma single company or organizationc. Remuneration: Total annual payment of 1 million yen or more received from asingle company or organization
d. Return on equity/stock: Total annual returns of 1 million yen or more received
from a single company, or a 5% or greater stock holding in said company.
e. Patent royalties: Total annual royalties of 1 million yen per patentf.

Research funding/subsidies: Total annual funding/subsidies of 2 million yen
provided by a single company or organization to the research institute, center, orlaboratory with which the author is affiliated.

g. Scholarships and other donations: Total annual scholarships/donations of 2 million
yen provided by a single company or organization to the research institute, center,or laboratory with which the author is affiliated.
h. Corporate and other sponsorship: Authors must declare a COI if they belong to a
research institute that receives sponsorship from a corporation or other entity.
i.

Others: Total annual payment of 50,000 yen or more received from a single
company or organization for travel expenses and gifts that are not directly related
to the author’s research.

5